Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company, on Thursday announced final data from the Phase one clinical trial of its investigational breast cancer vaccine (NCT04674306) at the 2025 San Antonio Breast Cancer Symposium (SABCS).
The trial was carried out in partnership with Cleveland Clinic and funded by a grant from the US Department of Defence.
Final Phase one results revealed that the investigational vaccine met all major primary endpoints. It was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants.
Topline Phase one results indicated that all major primary endpoints were met. It assessed safety and monitored immune response to an investigational vaccine targeting alpha-lactalbumin (aLA).
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
Genmab completes tender offer for Merus and opens subsequent offering period
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines